- Home
- RGTI vs EWTX Comparison
RGTI vs EWTX Comparison
Compare RGTI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGTI | EWTX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.3B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RGTI | EWTX |
|---|---|---|
| Price | $12.11 | $45.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $27.69 | ★ $55.42 |
| AVG Volume (30 Days) | ★ 11.8M | 1.5M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.78 | N/A |
| EPS | N/A | ★ 8.86 |
| Revenue | ★ $13,102,000.00 | N/A |
| Revenue This Year | $228.15 | N/A |
| Revenue Next Year | $88.82 | N/A |
| P/E Ratio | ★ N/A | $5.41 |
| Revenue Growth | ★ 59.86 | N/A |
| 52 Week Low | $9.19 | $19.76 |
| 52 Week High | $31.65 | $48.51 |
Technical Indicators
Market Signals| Indicator | RGTI | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 63.41 |
| Support Level | $11.11 | $37.22 |
| Resistance Level | $12.59 | $47.36 |
| Average True Range (ATR) | 0.89 | 3.02 |
| MACD | 0.23 | 1.04 |
| Stochastic Oscillator | 73.48 | 75.75 |
Price Performance
Historical ComparisonAbout RGTI Rigetti Computing Inc.
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.